The hazard ratio for the 125-mg daily dose measured 1.28 (P = not significant).
The PS-matched hazard ratio for composite CVD was 1.16 (95% CI, 0.99-1.34) in XOI initiators vs those with untreated hyperuricemia.
In subgroup analyses, the PS-matched hazard ratio for composite CVD adjusted for serum uric acid levels was 1.10 (95% CI, 0.74-1.64) among XOI initiators.
RESULTS: The hazard ratio for AGTR1 homozygous C/C status was 0.37.
After adjustment for covariates, the hazard ratio for nonfatal AMI was 0.72 (95% CI = 0.52-0.99, P = 0.044).
Table 4 Hazard ratio for moderate a second injury in relation to first injury type.
Data from CVD risk study on 5000 people was used to estimate hazard ratio for death.
Cox proportional hazards analysis showed a significant negative association between PD24 and long-term mortality (0.82 hazard ratio for each 10% change).
CONCLUSIONS: The EPC adjudication identified fewer HF hospitalizations than did the investigator reported method with no change in the hazard ratio for this end point.
After adjustments for baseline differences, no significant difference in mortality was detected (hazard ratio for rhythm-control vs rate-control = 0.696, 95% CI 0.453-1.07, P = 0.098).
The adjusted hazard ratio for 1-year MACCE was 1.31 (95% confidence interval: 1.01-1.69; p = 0.01) for on pump versus off pump.
